Compass Therapeutics
CMPX
173 hedge funds and large institutions have $881M invested in Compass Therapeutics in 2025 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 60 increasing their positions, 34 reducing their positions, and 10 closing their positions.
490% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 10
167% more funds holding in top 10
Funds holding in top 10: 3 → 8 (+5)
76% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 34
67% more capital invested
Capital invested by funds: $529M → $881M (+$353M)
38% more funds holding
Funds holding: 125 → 173 (+48)
16.95% less ownership
Funds ownership: 109.23% → 92.29% (-17%)
80% less call options, than puts
Call options by funds: $2K | Put options by funds: $10K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$16.7M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$13.9M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
+$12.9M |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$11.7M |
| 5 |
BlackRock
New York
|
+$9.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$17.8M |
| 2 |
Blackstone Inc
New York
|
-$17.1M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$8.23M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$7.84M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.19M |
CMPX Hedge Fund Activity: Q4 2025 in Review
173 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q4 2025, worth a combined $881M — up 67% from $529M a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new CMPX positions and 10 closed out — a net gain of 49 holders — while 60 added to existing stakes and 34 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $16.7M. The largest seller was MPM BioImpact, exiting entirely with an estimated $17.8M sold.
- 173 institutional investors held Compass Therapeutics (CMPX) as of Q4 2025, up from 125 in Q3 2025.
- Funds reported $881M of Compass Therapeutics stock for Q4 2025, up 67% quarter-over-quarter.
- 59 funds opened new Compass Therapeutics positions in Q4 2025 and 10 closed out, a net change of +49 holders.
- The largest Compass Therapeutics buyer in Q4 2025 was Deerfield Management, an estimated $16.7M added.
- The largest Compass Therapeutics seller in Q4 2025 was MPM BioImpact, an estimated $17.8M sold.
Based on aggregated 13F filings for Q4 2025.